HUTCHMED’s sovleplenib receives US FDA Orphan Drug Designation for primary ITP. Explore the regulatory implications and Phase III ESLIM-01 results.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
HUTCHMED (China) announced on October 29, 2026, that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation to sovleplenib for primary immune thrombocytopenia (ITP), an autoimmune disorder characterised by low platelet counts and an increased risk of bleeding.
Sovleplenib is an investigational, selective, orally administered spleen tyrosine kinase (Syk) inhibitor. The designation may provide access to development incentives, including tax credits for eligible clinical testing, potential exemption from applicable FDA user fees, and regulatory guidance. If the drug is subsequently approved for the designated indication and meets the relevant requirements, it could also qualify for seven years of US orphan-drug exclusivity.
Syk Inhibition Addresses an Established Mechanism in ITP
Primary ITP develops when immune mechanisms accelerate platelet destruction and may also impair platelet production. Patients can experience bruising, bleeding, fatigue and reduced quality of life. Although several treatment options are available, some patients have persistent disease, relapse or inadequate responses to previous therapies.
Sovleplenib inhibits Syk, a signalling protein involved in immune-cell receptor pathways. In ITP, Syk-dependent signalling contributes to the phagocytosis of antibody-coated platelets. Inhibiting this pathway provides a rationale for investigating sovleplenib as an oral treatment, although its clinical value must be established through clinical evidence and regulatory assessment.
Phase III ESLIM-01 Results Support Further Development in Chronic ITP
The clinical programme has already generated Phase III evidence in China. In the randomised, double-blind, placebo-controlled ESLIM-01 trial, 188 adults with chronic primary ITP who had received at least one previous treatment were assigned to sovleplenib or placebo.
Published results in The Lancet Haematology showed a durable platelet response in 48% of patients receiving sovleplenib (61 of 126), compared with none of the 62 patients receiving placebo at 24 weeks. The difference was statistically significant (p<0.0001). Treatment-emergent adverse events were reported in 99% of patients receiving sovleplenib and 85% receiving placebo; most were mild or moderate. Serious adverse events occurred in 21% and 18%, respectively.
These findings support further development in chronic primary ITP, but the trial was conducted in China and does not independently establish the drug’s benefit-risk profile in a US population. The October 29 designation announcement did not report new clinical efficacy or safety findings.
Chinese Applications Follow a Separate Regulatory Pathway
Sovleplenib’s regulatory progress in China provides additional context for the programme. The NMPA accepted the resubmitted NDA for primary ITP in February 2026 and granted it priority review. The application is supported by ESLIM-01. The resubmission followed additional manufacturing validation and stability requirements.
The NMPA accepted the NDA for warm antibody autoimmune hemolytic anaemia (wAIHA) and granted priority review in April 2026. That application is supported by the Phase II/III ESLIM-02 programme, which evaluated sovleplenib in adults with wAIHA.
These applications concern separate indications and remain distinct from the US orphan designation. Neither Chinese regulatory pathway should be interpreted as evidence of FDA approval, and the October 29 announcement did not establish a US marketing application timeline.
Potential Commercial Implications
The designation may support US development by providing access to certain financial and regulatory incentives. Potential seven-year orphan-drug exclusivity could offer additional protection following approval, subject to applicable regulatory requirements.
HUTCHMED retains worldwide rights to sovleplenib, giving the company control over its development and potential commercialisation strategy across markets. However, the designation alone does not establish the drug’s eventual market position, commercial prospects or likelihood of approval.
What the Milestone Establishes
The FDA’s Orphan Drug Designation recognises sovleplenib’s development for a rare disease and may support further investment in the US programme. Its significance lies in the additional regulatory framework available to the developer, rather than a change in the drug’s clinical evidence.
The next important milestones would be any disclosed US clinical or regulatory submissions and decisions on the pending Chinese applications. Until a marketing authorisation is granted, sovleplenib remains investigational for the designated US indication.
References
Phase III Study on HMPL-523 for Treatment of ITP, ClinicalTrials.gov ID NCT05029635
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia, HUTCHMED, 29 October 2029
Hu Y et al, Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024 Aug;11(8):e567-e579. Epub 2024 Jun 14. PMID: 38885672. https://doi.org/10.1016/s2352-3026(24)00139-x
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.